Suyog Kamatkar

Suyog Kamatkar

Auto-generated profile, based on publicly available information

Suyog Kamatkar

Division of Neonatology Perinatal Institute Cincinnati Children’s Hospital Medical Center Cincinnati Ohio USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2021 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
MHMatthijs W. Van Hoogdalem
Matthijs W. Van Hoogdalem
TJTrevor Nigel Johnson
Trevor Nigel Johnson
BMBrooks T. McPhail
Brooks T. McPhail
SKSuyog Kamatkar
Suyog Kamatkar
SWScott L. Wexelblatt
Scott L. Wexelblatt
Tomoyuki MizunoTomoyuki Mizuno
Tomoyuki Mizuno

1 July 2011 in Journal of Neurotrauma
Verified
Journal Article
Closed access
SZSyed Nabeel Zafar
Syed Nabeel Zafar
AIAftab Iqbal
Aftab Iqbal
MFMauricio F. Farez
Mauricio F. Farez
SKSuyog Kamatkar
Suyog Kamatkar
MMMarc A. de Moya
Marc A. de Moya
Many studies have addressed the question of whether intensive insulin therapy (IIT) provides better outcomes for brain-injured patients than does conventional insulin therapy (CIT), with conflicting results. We performed a systematic review and meta-analysis of the literature to estimate the effect of IIT on patients with brain injury. We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), and citations of key articles and selected “all randomized controlled trials” (RCTs) comparing the effect of IIT to CIT among adult patients with acute brain injury (traumatic brain injury, stroke, subarachnoid hemorrhage, and encephalitis). Of the 2807 studies, we identified 9 RCTs with a total of 1160 patients for analysis. IIT did not appear to decrease the risk of in-hospital or late mortality (RR=1.04, 95% CI=0.75, 1.43 and RR=1.07, 95%CI=0.91, 1.27 respectively). No significant heterogeneity was found (I2=0.0%). IIT also did not have a protective effect on long-term neurological outcomes (LTNO) (RR=1.10, 95% CI=0.96, 1.27). IIT, however, did decrease the rate of infections (RR=0.76, 95% CI=0.58, 0.98). Heterogeneity was present (I2=64%), which was eliminated upon sensitivity analysis bringing the RR to 0.66 (95% CI=0.55, 0.80, I2=0%). IIT increased the rate of hypoglycemic episodes (RR=1.72, 95% CI=1.20, 2.46) however there was intractable heterogeneity present (I2=89%), which did not resolve upon sensitivity analysis. We found no evidence of publication bias by Egger's test (p=0.50). To conclude, IIT has no mortality or LTNO benefit to patients with brain injury, but is beneficial at decreasing infection rates.

31 December 2011 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
BLBernard T. Lee
Bernard T. Lee
MDMargaret M. Duggan
Margaret M. Duggan
MKMaureen T. Keenan
Maureen T. Keenan
SKSuyog Kamatkar
Suyog Kamatkar
RQRobert M. Quinlan
Robert M. Quinlan
YCYoon S. Chun
Yoon S. Chun